Table 5 (Abstract P61).
Pre-Treatment Blood-Based | Post-Treatment Blood-Based | |||||
|---|---|---|---|---|---|---|
16-Gene mRNA Signature | 8-Gene mRNA Signature | |||||
Melanoma | Training | Test | Test | Training | Test | Test |
Cases | N=210 | N=150 | N=150 | N=210 | N=150 | N=150 |
Biomarker | Response | Response | Survival | Response | Response | Survival |
Sensitivity | 96.4% | 65.0% | 74.4% | 85.7% | 70.0% | 69.8% |
Specificity | 66.5% | 59.2% | 55.1% | 64.3% | 60.8% | 59.8% |
NPV | 99.2% | 91.7% | 84.3% | 96.7% | 92.9% | 83.1% |
AUC | 0.8634 | 0.6376 | 0.6785 | 0.7853 | 0.6125 | 0.6512 |